Key facts
- Eikonoklastes Therapeutics’s last known valuation is $100.0M (Jul 2025).
- It has raised $25.0M across 6 recorded rounds; the latest was Early Stage VC ($13.6M) in Jul 2025.
- Notable investors include JobsOhio Ventures, Rev1 Ventures, CincyTech.
- Eikonoklastes Therapeutics has filed 6 Form Ds with the SEC since 2020, most recently Jul 2025 ($13.6M sold to 14 investors).
- Status: Privately Held (backing).
Investors
3- ·Post-money valuations for all 6 rounds
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Eikonoklastes Therapeutics
Funding rounds
6 roundsAbout Eikonoklastes Therapeutics
Developer of disruptive therapies designed to assist in the treatment of solid tumors and other pathologic conditions. The company's immunotherapies target the cell surface receptor by utilizing a recombinant fusion protein, enabling healthcare professionals to treat triple-negative breast cancer, ovarian cancer, metastatic melanoma, and a broad range of other solid tumors.
- Sector
- Healthcare
- HQ
- Cincinnati, OH, United States
- Founded
- 2019
- Employees
- 8
- Website
- eikonoklastes.com/
- Ownership
- Privately Held (backing)
Eikonoklastes Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Eikonoklastes Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Eikonoklastes Therapeutics in its N-PORT filings yet. We sweep new filings monthly.